{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:14:10Z","timestamp":1791828850899,"version":"4.3.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.jbspin.2010.11.012","type":"journal-article","created":{"date-parts":[[2011,1,4]],"date-time":"2011-01-04T09:31:35Z","timestamp":1294133495000},"page":"484-487","source":"Crossref","is-referenced-by-count":32,"title":["Rituximab in rheumatoid arthritis and the risk of malignancies: Report from a French cohort"],"prefix":"10.1016","volume":"78","author":[{"given":"Samy","family":"Slimani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Lukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Combe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2010.11.012_bib0005","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","article-title":"Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation","volume":"97","author":"Colombat","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jbspin.2010.11.012_bib0010","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/blood.V108.11.486.486","article-title":"Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma (FL): survival analysis with extended follow-up (F\/up) of 7 years","volume":"108","author":"Colombat","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jbspin.2010.11.012_bib0015","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2010.11.012_bib0020","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2010.11.012_bib0025","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2010.11.012_bib0030","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jbspin.2010.01.008","article-title":"Safety of rituximab in rheumatoid arthritis patients with a history of severe or recurrent bacterial infection: observational study of 30 cases in everyday practice","volume":"77","author":"Toussirot","year":"2010","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2010.11.012_bib0035","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1002\/art.23059","article-title":"Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis","volume":"56","author":"Keystone","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2010.11.012_bib0040","unstructured":"van Vollenhoven R, Emery P, Bingham C, et al. Extended follow-up of the long-term safety of rituximab in rheumatoid arthritis. Ann Rheum Dis 2007;66:88 [abstract]."},{"key":"10.1016\/j.jbspin.2010.11.012_bib0045","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.jbspin.2010.11.012_bib0050","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1200\/JCO.1998.16.4.1635","article-title":"Peripheral T-cell lymphoma after anti-CD20 antibody therapy","volume":"16","author":"Tetreault","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jbspin.2010.11.012_bib0055","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood.V93.7.2427","article-title":"Peripheral T-cell lymphoma following rituximab therapy for B-cell lymphoma","volume":"93","author":"Micallef","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jbspin.2010.11.012_bib0060","first-page":"1636","article-title":"Peripheral T-cell lymphoma after anti-CD20 antibody therapy","volume":"16","author":"Maloney","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jbspin.2010.11.012_bib0065","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/rheumatology\/ken130","article-title":"Cancer risk in hospitalized rheumatoid arthritis patients","volume":"47","author":"Hemminki","year":"2008","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2010.11.012_bib0070","doi-asserted-by":"crossref","unstructured":"Parikh-Patel A, White RH, Allen M, et al. Risk of cancer among rheumatoid arthritis patients in California. Cancer Causes Control 2009;20:1001\u201310.","DOI":"10.1007\/s10552-009-9298-y"},{"key":"10.1016\/j.jbspin.2010.11.012_bib0075","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/0959-8049(96)00210-9","article-title":"Rheumatoid arthritis and cancer risk","volume":"32A","author":"Mellemkjaer","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jbspin.2010.11.012_bib0080","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/art.1780400906","article-title":"Rheumatoid arthritis and the risk of malignancy","volume":"40","author":"Cibere","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2010.11.012_bib0085","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/art.20311","article-title":"Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2010.11.012_bib0090","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0889-857X(05)70368-9","article-title":"Does methotrexate increase the risk of infection or malignancy?","volume":"23","author":"Kanik","year":"1997","journal-title":"Rheum Dis Clin N Am"},{"key":"10.1016\/j.jbspin.2010.11.012_bib0095","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/art.23716","article-title":"Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate","volume":"59","author":"Buchbinder","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2010.11.012_bib0100","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1136\/ard.2004.033993","article-title":"Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists","volume":"64","author":"Askling","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2010.11.012_bib0105","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/art.22864","article-title":"Biologic treatment of rheumatoid arthritis and the risk of malignancy. Analyses from a large us observational study","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2010.11.012_bib0110","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/ard.2004.030528","article-title":"Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas","volume":"64","author":"Geborek","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2010.11.012_bib0115","doi-asserted-by":"crossref","unstructured":"Askling J, Baecklund E, Granath F et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 2009;68:648\u2013653.","DOI":"10.1136\/ard.2007.085852"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X10003258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X10003258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T07:18:49Z","timestamp":1592205529000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X10003258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S1297319X10003258"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2010.11.012","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}